A Randomized, Triple-blind, Placebo- and Positive-Controlled, Parallel Group Study of the Effect of Buprenorphine Delivered by the Buprenorphine Transdermal System (BTDS) at Doses up to 80 Mcg/Hour and Naltrexone on ECG Intervals in Healthy Adult Subjects

Trial Profile

A Randomized, Triple-blind, Placebo- and Positive-Controlled, Parallel Group Study of the Effect of Buprenorphine Delivered by the Buprenorphine Transdermal System (BTDS) at Doses up to 80 Mcg/Hour and Naltrexone on ECG Intervals in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2013

At a glance

  • Drugs Buprenorphine (Primary) ; Moxifloxacin; Naltrexone
  • Indications Pain
  • Focus Pharmacodynamics
  • Sponsors Purdue Pharma
  • Most Recent Events

    • 08 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top